Cantor Fitzgerald Forecasts Innoviva FY2026 Earnings

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Innoviva in a research report issued to clients and investors on Friday, July 11th. Cantor Fitzgerald analyst S. Seedhouse expects that the biotechnology company will earn $1.84 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $26.00 target price on the stock. The consensus estimate for Innoviva's current full-year earnings is $0.33 per share.

Innoviva (NASDAQ:INVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter. Innoviva had a positive return on equity of 15.77% and a negative net margin of 16.15%. The company had revenue of $88.63 million for the quarter.

Other equities analysts have also issued reports about the company. HC Wainwright began coverage on Innoviva in a research report on Monday. They set a "buy" rating and a $40.00 target price on the stock. Wall Street Zen raised Innoviva from a "hold" rating to a "buy" rating in a research report on Wednesday, April 30th.

Innoviva Stock Down 1.8%

Shares of NASDAQ:INVA traded down $0.37 during trading on Monday, reaching $19.88. 970,643 shares of the stock were exchanged, compared to its average volume of 714,251. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.48 and a quick ratio of 2.30. Innoviva has a 1-year low of $16.67 and a 1-year high of $22.00. The stock has a fifty day moving average of $19.89 and a two-hundred day moving average of $18.64. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -19.68 and a beta of 0.37.

Institutional Investors Weigh In On Innoviva

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue raised its position in Innoviva by 7.7% in the 2nd quarter. State of Alaska Department of Revenue now owns 32,874 shares of the biotechnology company's stock valued at $659,000 after buying an additional 2,349 shares during the last quarter. Ballentine Partners LLC purchased a new stake in Innoviva in the 2nd quarter valued at $350,000. GAMMA Investing LLC raised its position in Innoviva by 58.9% in the 2nd quarter. GAMMA Investing LLC now owns 7,146 shares of the biotechnology company's stock valued at $144,000 after buying an additional 2,648 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in Innoviva by 2.8% in the 2nd quarter. Exchange Traded Concepts LLC now owns 180,982 shares of the biotechnology company's stock valued at $3,636,000 after purchasing an additional 4,957 shares during the period. Finally, Parallel Advisors LLC grew its stake in Innoviva by 157.5% in the 2nd quarter. Parallel Advisors LLC now owns 1,849 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 1,131 shares during the period. 99.12% of the stock is owned by hedge funds and other institutional investors.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.